Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: Clinical trial protocol

Ashish H. Shah, Amade Bregy, Deborah O Heros, Ricardo J Komotar, John Goldberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND: Although there have been significant advances in understanding the basic pathogenesis of glioblastoma multiforme, the median survival of patients has changed little in the past 25 years. Recent studies have suggested that immune modulation through dendritic cell (DC) vaccines may stimulate the immune system against tumor antigens and potentially increase survival. OBJECTIVE: To determine whether the use of adjuvant vaccination with autologous DCs (matured in situ after being loaded with tumor cell lysate derived from autologous refractory gliomas) is safe, feasible, and beneficial for adult and pediatric patients with recurrent high-grade gliomas. METHODS: The study design is a single-center, nonrandomized, open phase I clinical trial. A total of 20 patients with malignant gliomas will be enrolled preoperatively over 2 years. Patients will be given adjuvant vaccination with autologous DCs loaded with tumor lysate after maximal safe surgical resection. EXPECTED OUTCOMES: Using topical imiquimod before vaccination, it is anticipated that the immune response in vaccinated patients and potentially Overall survival will be greater than that demonstrated in the literature. We anticipate that there will be minimal side effects (minor dermatitis) associated with this treatment. DISCUSSION: In the current trial, we assess immune response, safety, and survival using a novel vaccine protocol developed in Belgium that seems to markedly increase survival of certain subjects. Nevertheless, larger randomized clinical studies need to be performed to evaluate fully the efficacy of this therapy for both recurrent and newly diagnosed glioblastoma.

Original languageEnglish
Pages (from-to)863-867
Number of pages5
JournalNeurosurgery
Volume73
Issue number5
DOIs
StatePublished - Nov 1 2013

Fingerprint

Clinical Protocols
Glioma
Dendritic Cells
Vaccines
Clinical Trials
Pediatrics
Survival
Vaccination
Glioblastoma
imiquimod
Clinical Trials, Phase I
Belgium
Neoplasm Antigens
Dermatitis
Immune System
Neoplasms
Safety
Therapeutics

Keywords

  • Clinical trial
  • Dendritic cell vaccine
  • Malignant gliomas

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects : Clinical trial protocol. / Shah, Ashish H.; Bregy, Amade; Heros, Deborah O; Komotar, Ricardo J; Goldberg, John.

In: Neurosurgery, Vol. 73, No. 5, 01.11.2013, p. 863-867.

Research output: Contribution to journalArticle

Shah, Ashish H. ; Bregy, Amade ; Heros, Deborah O ; Komotar, Ricardo J ; Goldberg, John. / Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects : Clinical trial protocol. In: Neurosurgery. 2013 ; Vol. 73, No. 5. pp. 863-867.
@article{512594d78ad347769d8d906c24b5110e,
title = "Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: Clinical trial protocol",
abstract = "BACKGROUND: Although there have been significant advances in understanding the basic pathogenesis of glioblastoma multiforme, the median survival of patients has changed little in the past 25 years. Recent studies have suggested that immune modulation through dendritic cell (DC) vaccines may stimulate the immune system against tumor antigens and potentially increase survival. OBJECTIVE: To determine whether the use of adjuvant vaccination with autologous DCs (matured in situ after being loaded with tumor cell lysate derived from autologous refractory gliomas) is safe, feasible, and beneficial for adult and pediatric patients with recurrent high-grade gliomas. METHODS: The study design is a single-center, nonrandomized, open phase I clinical trial. A total of 20 patients with malignant gliomas will be enrolled preoperatively over 2 years. Patients will be given adjuvant vaccination with autologous DCs loaded with tumor lysate after maximal safe surgical resection. EXPECTED OUTCOMES: Using topical imiquimod before vaccination, it is anticipated that the immune response in vaccinated patients and potentially Overall survival will be greater than that demonstrated in the literature. We anticipate that there will be minimal side effects (minor dermatitis) associated with this treatment. DISCUSSION: In the current trial, we assess immune response, safety, and survival using a novel vaccine protocol developed in Belgium that seems to markedly increase survival of certain subjects. Nevertheless, larger randomized clinical studies need to be performed to evaluate fully the efficacy of this therapy for both recurrent and newly diagnosed glioblastoma.",
keywords = "Clinical trial, Dendritic cell vaccine, Malignant gliomas",
author = "Shah, {Ashish H.} and Amade Bregy and Heros, {Deborah O} and Komotar, {Ricardo J} and John Goldberg",
year = "2013",
month = "11",
day = "1",
doi = "10.1227/NEU.0000000000000107",
language = "English",
volume = "73",
pages = "863--867",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects

T2 - Clinical trial protocol

AU - Shah, Ashish H.

AU - Bregy, Amade

AU - Heros, Deborah O

AU - Komotar, Ricardo J

AU - Goldberg, John

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND: Although there have been significant advances in understanding the basic pathogenesis of glioblastoma multiforme, the median survival of patients has changed little in the past 25 years. Recent studies have suggested that immune modulation through dendritic cell (DC) vaccines may stimulate the immune system against tumor antigens and potentially increase survival. OBJECTIVE: To determine whether the use of adjuvant vaccination with autologous DCs (matured in situ after being loaded with tumor cell lysate derived from autologous refractory gliomas) is safe, feasible, and beneficial for adult and pediatric patients with recurrent high-grade gliomas. METHODS: The study design is a single-center, nonrandomized, open phase I clinical trial. A total of 20 patients with malignant gliomas will be enrolled preoperatively over 2 years. Patients will be given adjuvant vaccination with autologous DCs loaded with tumor lysate after maximal safe surgical resection. EXPECTED OUTCOMES: Using topical imiquimod before vaccination, it is anticipated that the immune response in vaccinated patients and potentially Overall survival will be greater than that demonstrated in the literature. We anticipate that there will be minimal side effects (minor dermatitis) associated with this treatment. DISCUSSION: In the current trial, we assess immune response, safety, and survival using a novel vaccine protocol developed in Belgium that seems to markedly increase survival of certain subjects. Nevertheless, larger randomized clinical studies need to be performed to evaluate fully the efficacy of this therapy for both recurrent and newly diagnosed glioblastoma.

AB - BACKGROUND: Although there have been significant advances in understanding the basic pathogenesis of glioblastoma multiforme, the median survival of patients has changed little in the past 25 years. Recent studies have suggested that immune modulation through dendritic cell (DC) vaccines may stimulate the immune system against tumor antigens and potentially increase survival. OBJECTIVE: To determine whether the use of adjuvant vaccination with autologous DCs (matured in situ after being loaded with tumor cell lysate derived from autologous refractory gliomas) is safe, feasible, and beneficial for adult and pediatric patients with recurrent high-grade gliomas. METHODS: The study design is a single-center, nonrandomized, open phase I clinical trial. A total of 20 patients with malignant gliomas will be enrolled preoperatively over 2 years. Patients will be given adjuvant vaccination with autologous DCs loaded with tumor lysate after maximal safe surgical resection. EXPECTED OUTCOMES: Using topical imiquimod before vaccination, it is anticipated that the immune response in vaccinated patients and potentially Overall survival will be greater than that demonstrated in the literature. We anticipate that there will be minimal side effects (minor dermatitis) associated with this treatment. DISCUSSION: In the current trial, we assess immune response, safety, and survival using a novel vaccine protocol developed in Belgium that seems to markedly increase survival of certain subjects. Nevertheless, larger randomized clinical studies need to be performed to evaluate fully the efficacy of this therapy for both recurrent and newly diagnosed glioblastoma.

KW - Clinical trial

KW - Dendritic cell vaccine

KW - Malignant gliomas

UR - http://www.scopus.com/inward/record.url?scp=84886593015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886593015&partnerID=8YFLogxK

U2 - 10.1227/NEU.0000000000000107

DO - 10.1227/NEU.0000000000000107

M3 - Article

C2 - 23867302

AN - SCOPUS:84886593015

VL - 73

SP - 863

EP - 867

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -